Assembly Biosciences | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (19)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
Article By: ChinaBio® Today
Saturday, April 30, 2022 1:45 PM EDT
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings total funds raised since inception to $140 million.
In this article: BMY, 000963.SZ, ARWR, ASMB, IMAB, LIAN, 6628.HK, 300633.SZ
Read
Dow Up Triple Digits, Poised To Snap Three-Day Skid
Article By: Schaeffers Research
Thursday, September 2, 2021 12:23 PM EDT
The Dow Jones Industrial Index is staging a bounce off yesterday's lukewarm trading, last seen up 150 points, and set to snap a three-day losing streak.
In this article: AAPL, GSAT, NDX, SPX, VIX, DJI, ABBV, ASMB
Read
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Article By: Benzinga
Sunday, June 20, 2021 11:19 AM EDT
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
In this article: ALNY, DRRX, NVAX, ABBV, RGLS, RDUS, CAPR, NTLA, ABUS, ASND, ASMB, AKRO, FULC, VIR, DAWN, OMIC, CNTA, IVA, IPHA
Read
The Week Ahead In Biotech (Aug. 24-29): Lipocine Binary Event, Liver Congress In The Spotlight
Article By: Benzinga
Sunday, August 23, 2020 3:17 PM EDT
After seeing strength earlier, biotech stocks came under pressure in the past week. With the earnings season tapering and not much noise on the coronavirus front, the sector reacted to clinical readouts, M&A announcements, and adverse FDA rulings.
In this article: EIGR, ARWR, CBAY, VKTX, ADAP, ASMB, LPCN, MIRM, AXLA
Read
Week In Review: BeiGene Signs $540 Million Deal For China Rights To Three HBV Candidates
Article By: ChinaBio® Today
Saturday, July 25, 2020 1:21 PM EDT
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Bio in a $540 million agreement. BeiGene, which will make a $40 million upfront payment, is responsible for $500 million in milestones.
In this article: CASI, JUNO, HCM, BGNE, ASMB
Read
All Posts

Latest Tweets for $ASMB

No tweets yet!

PARTNER HEADLINES